Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan

Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE

(2015) I. Doycheva et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

(2015) Raymond Kwok et al.   GUT

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study

(2015) Edith M. Koehler et al.   HEPATOLOGY

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

(2015)   JOURNAL OF HEPATOLOGY

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

(2015) Mohamed Asrih et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations

(2014) Victor de Lédinghen et al.   JOURNAL OF HEPATOLOGY

Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy

(2014) Thomas Karlas et al.   PLoS One

Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study

(2013) Joanne R. Morling et al.   JOURNAL OF HEPATOLOGY

Screening for liver fibrosis by using FibroScan® and FibroTest in patients with diabetes

(2012) Victor de Lédinghen et al.   DIGESTIVE AND LIVER DISEASE

A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease

(2012) Stephen P. Casey et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

(2011) Robert P. Myers et al.   HEPATOLOGY

Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®

(2011) Victor de Lédinghen et al.   JOURNAL OF HEPATOLOGY

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

(2011) M. Sasso et al.   JOURNAL OF VIRAL HEPATITIS

Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors

(2011) Nathalie C. Leite et al.   LIVER INTERNATIONAL

Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years

(2010) D. Roulot et al.   GUT

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

(2010) V. W.-S. Wong et al.   GUT

Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes

(2010) Magali Sasso et al.   ULTRASOUND IN MEDICINE AND BIOLOGY

Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis

(2009) Kenneth Cusi   Clinics in Liver Disease

Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes

(2008) S JACQUEMINET et al.   Clinical Gastroenterology and Hepatology

Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

(2008) Mireen Friedrich–Rust et al.   GASTROENTEROLOGY

Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome

(2008) Dominique Roulot et al.   JOURNAL OF HEPATOLOGY